A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Takeda
Tempus AI
Actym Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Ikena Oncology
Pfizer
Elevation Oncology
Kymab Limited
Novartis
NantCell, Inc.
Ikena Oncology
Fate Therapeutics
Fate Therapeutics
Hoffmann-La Roche
Montefiore Medical Center
MacroGenics
Tocagen Inc.
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
sigma-tau i.f.r. S.p.A.
Masonic Cancer Center, University of Minnesota
Calando Pharmaceuticals